Merck and Eisai’s Lenvima-Ketruda combo flunks first-line melanoma trial fkansteiner Fri, 04/07/2023 – 09:49 More: Merck and Eisai's Lenvima-Ketruda combo flunks first-line melanoma trial Source: fierce
read moreAbbVie, J&J pull 2 Imbruvica accelerated approvals in lymphoma, giving way to AZ and BeiGene aliu Fri, 04/07/2023 – 09:47 More: AbbVie, J&J pull 2 Imbruvica accelerated approvals in lymphoma, giving way to AZ and BeiGene Source: fierce
read moreIdorsia petitions DEA to de-schedule its insomnia drug—plus Merck and Eisai rivals kdunleavy Fri, 04/07/2023 – 07:52 More: Idorsia petitions DEA to de-schedule its insomnia drug—plus Merck and Eisai rivals Source: fierce
read moreGilead caused injuries while waiting to develop safer HIV drugs, lawsuit claims zbecker Thu, 04/06/2023 – 11:40 More: Gilead caused injuries while waiting to develop safer HIV drugs, lawsuit claims Source: fierce
read morePfizer escapes proposed class action lawsuit over patient copay assistance esagonowsky Thu, 04/06/2023 – 11:03 More: Pfizer escapes proposed class action lawsuit over patient copay assistance Source: fierce
read moreAstraZeneca to face tough FDA scrutiny with Imfinzi-Lynparza combo in ovarian cancer: analyst aliu Thu, 04/06/2023 – 10:24 More: AstraZeneca to face tough FDA scrutiny with Imfinzi-Lynparza combo in ovarian cancer: analyst Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals